Sichuan Goldstone Asia Pharmaceutical Inc. Overview
Sichuan Goldstone Asia Pharmaceutical Inc., a company based in Chengdu, China, has been making significant strides in the industrial sector since its founding in 2001. Specializing in the research, development, manufacturing, and sales of plastic composite pipes and vacuum coating machines, the company has established a strong presence both domestically and internationally. Listed on the Shenzhen Stock Exchange, Sichuan Goldstone Asia Pharmaceutical Inc. operates within the machinery industry, focusing on a diverse range of products and equipment.
Product Offerings
The company’s product portfolio includes a variety of reinforced pipe equipment. Key offerings encompass steel-reinforced corrugated pipes, reinforced composite polyethylene pipe production lines, fiberglass-reinforced RTP pipes, and steel-reinforced large diameter pipes. Additionally, the company manufactures steel-reinforced corrugated pipe socket and spigot making machines, abrasion-resistant industry pipes, extrusion pipe fittings, and perforated steel-reinforced polyethylene composite pipes.
In the realm of vacuum coating equipment, Sichuan Goldstone Asia Pharmaceutical Inc. provides low-emissivity glass coating lines, reflect glass magnetron sputtering coating lines, magnetron sputtering mirror coating production lines, and vacuum sputter systems for automotive car mirrors. The company also offers ITO/TCO glass coating machines, sputtering metallization machines, optical lens coating machines, roll web metallization machines, and air-to-air solar absorption strip sputtering production lines. Furthermore, the company has ventured into smart parking equipment, expanding its technological footprint.
Financial Overview
As of June 12, 2025, the close price of Sichuan Goldstone Asia Pharmaceutical Inc. was 9.9 CNY. The company’s stock has experienced fluctuations over the past year, with a 52-week high of 11.48 CNY on January 7, 2025, and a 52-week low of 6.71 CNY on April 8, 2025. The market capitalization stands at 3,217,968,762 CNY, reflecting the company’s substantial presence in the market. The price-to-earnings ratio is currently 56.0644, indicating the company’s valuation relative to its earnings.
Conclusion
Sichuan Goldstone Asia Pharmaceutical Inc. continues to be a key player in the machinery industry, with a strong focus on innovation and expansion in both domestic and international markets. The company’s diverse product range and strategic market positioning underscore its commitment to growth and technological advancement. For more information, interested parties can visit the company’s website at www.goldstone-group.com .